Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Applied Pharmaceutical Science to Start US Trial of 2nd Gen RET Inhibitor

publication date: Jan 24, 2022

Applied Pharmaceutical Science has been approved to start US trials of its next-gen selective RET inhibitor, a proposed therapy for solid tumor RET cancers. APS, a Beijing-Philadelphia company, is a precision therapy cancer biotech that develops cancer therapies based on cancer genetics, protein structure/function, synthetic medicinal chemistry, and verification via experiment and computation. The trial will enroll solid tumor patients with RET gene alterations or resistance to first-gen RET inhibitors. In Q2, APS plans to file an IND in China for the RET inhibitor and start a global trial. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital